The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Adalat LA 30 mg Prolonged-Release Tablet

30 milligram(s) Prolonged-release tablet

LTT Pharma LimitedPPA1562/036/002

Main Information

Trade NameAdalat LA 30 mg Prolonged-Release Tablet
Active SubstancesNifedipine
Strength30 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderLTT Pharma Limited
Licence NumberPPA1562/036/002

Group Information

ATC CodeC08CA Dihydropyridine derivatives
C08CA05 nifedipine


Withdrawn Date10/11/2020
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back